Merck, J&J's New Hepatitis C Treatments Fetch $31,000 in France
April 5, 2011
Though they are still under review by the European Medicines Agency, two new hepatitis C virus (HCV) treatments are already being prescribed to French patients. In December, telaprevir and boceprevir received special temporary authorization in a program for critically ill patients for whom no other effective treatment is available, said French pharmaceutical regulator AFSSAPS.
Used as a complement to existing HCV treatment, telaprevir, made by U.S.-based Johnson & Johnson and Vertex Pharmaceuticals Inc., and boceprevir, by Merck & Co., boost cure rates from roughly half of patients to between two-thirds and three-quarters, studies show. Both drugs are protease inhibitors made using the same technologies that led to improved HIV drugs. Approximately 500 patients currently are being treated in France, said Michel Bonjour, spokesperson for SOS Hepatites.
04.03.2011; Naomi Kresge; Carol Matlack
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)